Balyasny Asset Management LLC Akebia Therapeutics, Inc. Transaction History
Balyasny Asset Management LLC
- $61.9 Billion
- Q2 2025
A detailed history of Balyasny Asset Management LLC transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Balyasny Asset Management LLC holds 9,154 shares of AKBA stock, worth $28,011. This represents 0.0% of its overall portfolio holdings.
Number of Shares
9,154
Previous 1,245,494
99.27%
Holding current value
$28,011
Previous $2.39 Million
98.62%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding AKBA
# of Institutions
169Shares Held
105MCall Options Held
134KPut Options Held
262K-
Vanguard Group Inc Valley Forge, PA14.6MShares$44.7 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$35.6 Million0.0% of portfolio
-
State Street Corp Boston, MA8MShares$24.5 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA6.07MShares$18.6 Million0.0% of portfolio
-
Satter Management Co., L.P.5.75MShares$17.6 Million20.26% of portfolio
About Akebia Therapeutics, Inc.
- Ticker AKBA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 183,848,992
- Market Cap $563M
- Description
- Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...